<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242025000100009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[HeberFERON®, alternativa terapéutica para el cáncer de piel no melanoma en la atención primaria]]></article-title>
<article-title xml:lang="en"><![CDATA[HeberFERON®, therapeutic alternative for non-melanoma skin cancer in primary care]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Martori]]></surname>
<given-names><![CDATA[Meilyn]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler-Cárdenas]]></surname>
<given-names><![CDATA[Silvio Faustino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán-Marrero]]></surname>
<given-names><![CDATA[Karel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bello-Rivero]]></surname>
<given-names><![CDATA[Iraldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Policlínico Docente Dr. Carlos J. Finlay  ]]></institution>
<addr-line><![CDATA[Colón Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Matanzas  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro de Investigaciones Médico-Quirúrgicas  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro de Ingeniería Genética y Biotecnología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>47</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242025000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El cáncer de piel no melanoma constituye en Cuba, de manera sostenida, la primera causa de morbilidad por tumores malignos. El HeberFERON® se aplica como modalidad terapéutica, con experiencias favorables en esta enfermedad.  Objetivo: Evaluar la efectividad clínica del HeberFERON® en el cáncer cutáneo no melanoma.  Métodos: Se realizó un estudio observacional, descriptivo y prospectivo, entre el 1 de enero de 2017 y diciembre de 2023, en el Policlínico Docente Dr. Carlos J. Finlay, del municipio de Colón, provincia de Matanzas. Incluyó a 176 pacientes y 201 lesiones. La dosis fue de 10,5 millones de unidades internacionales, tres veces por semana, por tres semanas, perilesional e intradérmica. Las variables fueron: edad, sexo, fototipo, número de tumores, perfil tumoral, localización, tipo de tumor, tiempo de evolución, diámetro, variantes de cáncer, subtipos y diferenciación histológica. Se consideraron cuatro categorías de respuesta: completa, parcial, enfermedad estable y progresiva. Se incluyó la respuesta objetiva (completa más parcial). Se elaboró una historia clínica. Se utilizó el paquete de SPSS para el procesamiento estadístico y se cumplieron los principios éticos.  Resultados: Predominó el sexo masculino, el fototipo II y los pacientes con lesiones únicas. Prevalecieron los tumores primarios y la localización en cabeza-cara-cuello. En el tumor de mayor incidencia predominan las lesiones de 20 mm o menos. En la otra variante neoplásica, las lesiones superan con frecuencia los 20 mm. La respuesta objetiva en ambos tumores sobrepasó el indicador de efectividad, aunque en el carcinoma basocelular experimentó mejores respuestas.  Conclusiones: La mezcla de interferones fue efectiva en ambas variantes del cáncer de piel no melanoma.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Non-melanoma skin cancer is, in a sustained manner, the first cause of morbidity due to malignant tumors in Cuba. HeberFERON® is applied as a therapeutic modality with favorable experiences in this disease.  Objective:  To evaluate the clinical effectiveness of HeberFERON® in non-melanoma skin cancer.  Methods:  An observational, descriptive and prospective study was conducted between January 1st, 2017 and December 2023, at the Teaching Polyclinic Dr. Carlos J. Finlay, in the municipality of Colón, province of Matanzas. It included 176 patients and 201 lesions. The dose was 10.5 million international units, three times a week, for three weeks, perilesional and intradermal. The variables were age, sex, phototype, number of tumors, tumor profile, location, tumor type, evolution time, diameter, cancer variants, subtypes and histological differentiation. Four response categories were considered: complete, partial, stable and progressive disease. The objective response (complete plus partial) was included. A clinical record was prepared. The SPSS package was used for statistical processing and ethical principles were met.  Results:  Male sex, phototype II, and patients with single lesions predominated. Primary tumors and head-face-neck location predominated. In the tumor with the highest incidence, lesions of 20 mm or less predominated. In the other neoplastic variant, the lesions frequently exceed 20 mm. The objective response in both tumors exceeded the effectiveness indicator, although basal cell carcinoma experienced better responses.  Conclusions: The mixture of interferons was effective in both variants of non-melanoma skin cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de piel no melanoma]]></kwd>
<kwd lng="es"><![CDATA[carcinoma basocelular]]></kwd>
<kwd lng="es"><![CDATA[carcinoma epidermoide]]></kwd>
<kwd lng="es"><![CDATA[interferones]]></kwd>
<kwd lng="es"><![CDATA[interferón alfa 2b]]></kwd>
<kwd lng="es"><![CDATA[interferón gamma]]></kwd>
<kwd lng="en"><![CDATA[non-melanoma skin cancer]]></kwd>
<kwd lng="en"><![CDATA[basal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[squamous cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[interferons]]></kwd>
<kwd lng="en"><![CDATA[interferon alfa 2b]]></kwd>
<kwd lng="en"><![CDATA[interferon gamma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Prevención, diagnóstico y tratamiento del cáncer de piel]]></source>
<year>2023</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Keim]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Katalinic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2024</year>
<volume>16</volume>
<page-range>606</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Do Nascimento]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Furtado Cardoso de Moraes]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Costa Silva]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in non-Melanoma Skin Cancer Mortality in Brazil and its Macroregions]]></article-title>
<source><![CDATA[Rev bras cancerol]]></source>
<year>2022</year>
<volume>68</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Cancer Statistic 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2021</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>209-49</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Dirección de Registros Médicos y Estadísticas de Salud</collab>
<source><![CDATA[Anuario Estadístico de Salud 2022]]></source>
<year>2023</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Arias]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arias-Blanco]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Redondo-Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad y eficiencia de la teledermatoscopia en el manejo del cáncer de piel en atención primaria]]></article-title>
<source><![CDATA[SEMERGEN]]></source>
<year>2020</year>
<volume>46</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>553-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso-Belmonte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Montero-Vilchez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arias-Santiago]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Situación actual de la prevención del cáncer de piel: una revisión sistemática]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2022</year>
<volume>113</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>781-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmults]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Blitzblau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aasi]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2021</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1382-94</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmults]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Blitzblau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aasi]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2023</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1181-203</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peris]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fargnoli]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Garbe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2019</year>
<volume>118</volume>
<page-range>10-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vílchez-Márquez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borregón-Nofuentes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barchino-Ortíz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma basocelular cutáneo: diagnóstico y tratamiento en atención especializada dermatológica. Guía de Práctica Clínica de la AEDV]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2020</year>
<volume>111</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>291-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>CECMED</collab>
<source><![CDATA[HEBERFERON® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec)]]></source>
<year>2022</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Pupo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Manganelly-Fonseca]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tablada-Robinet]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad del HeberFERON en pacientes con carcinoma basocelular]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2021</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del-Río-Ysla]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu-Rivero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Matos-Pelegrin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultado terapéutico del uso del HeberFERON en pacientes con carcinoma basocelular]]></article-title>
<source><![CDATA[MediCiego]]></source>
<year>2020</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Rosales]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca-Núñez]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes-Gómez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad del HeberFERON en el tratamiento del carcinoma basocelular]]></article-title>
<source><![CDATA[Multimed]]></source>
<year>2023</year>
<volume>27</volume>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Fonseca]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[de la Rosa-Santana]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[López-Wilson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con HeberFERON en pacientes con carcinoma basocelular del Hospital Docente Clínico Quirúrgico &#8220;Dr. Miguel Enríquez&#8221;, La Habana]]></article-title>
<source><![CDATA[Gac Med Est]]></source>
<year>2020</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>122-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Suárez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roben-Aguilar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Acosta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal Cell Carcinoma Treated with HeberFERON. A Real-World Retrospective Study]]></article-title>
<source><![CDATA[Clin Oncol]]></source>
<year>2021</year>
<volume>6</volume>
<page-range>1872</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrá-Torres]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Rodríguez]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Ballester-Caballero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON]]></article-title>
<source><![CDATA[Arch méd Camagüey]]></source>
<year>2020</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez-Sañudo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Monzón-Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados del uso de HeberFERON en pacientes con carcinoma basocelular de alto riesgo en Matanzas]]></article-title>
<source><![CDATA[Rev Méd Electrón]]></source>
<year>2023</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morán-Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Arroyo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterios de Evaluación en Tumores Sólidos 1.1 (RECIST 1.1) en pacientes con cáncer primario y/o metastásico o enfermedad metastásica recurrente]]></article-title>
<source><![CDATA[Rev S Científica]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-12</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Asociación Médica Mundial</collab>
<source><![CDATA[Declaración de helsinki de la AMM - principios éticos para las investigaciones médicas con participantes humanos]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Ferney-Voltaire ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Médica Mundial]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ci&#261;&#380;y&#324;ska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kami&#324;ska&#8209;Winciorek]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence and clinical analysis of non-melanoma skin cancer]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2021</year>
<volume>11</volume>
<page-range>4337</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gürsel-Ürün]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fiçicio&#287;lu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Can]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical, Dermoscopic and Histopathological Evaluation of Basal Cell Carcinoma Subtypes]]></article-title>
<source><![CDATA[Dermatol Pract Concept]]></source>
<year>2023</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Martori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soler-Cárdenas]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Amador-García]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma epidermoide de piel tratado con HeberFERON®]]></article-title>
<source><![CDATA[Rev Méd Electrón]]></source>
<year>2022</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tejera-Vaquerizo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cañueto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nagore]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Es la estimación del tiempo de duplicación tumoral posible y útil en el cáncer de piel?]]></article-title>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2023</year>
<volume>114</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anasagasti-Angulo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García-Vega]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Barcelona-Pérez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2009</year>
<volume>9</volume>
<page-range>262</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-Porro]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Cárdenas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Iserm-Pérez]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serie de tres pacientes con carcinoma epidermoide periocular tratados con HeberFERON. Informe de caso]]></article-title>
<source><![CDATA[MediCiego]]></source>
<year>2021</year>
<volume>27</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
